BERKELEY, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 16, 2002--XOMA Ltd. (Nasdaq:XOMA - News) and Dyax Corp. (Nasdaq:DYAX - News) announced today they have entered into a cross-licensing agreement for antibody-related technologies. Under the agreement, Dyax receives a license to use XOMA's antibody expression technology for developing antibody products for itself and for Dyax collaborators. Dyax also receives a license for the production of antibodies under the XOMA patents. XOMA will receive license and royalty payments from Dyax in addition to a Dyax antibody library and a license to Dyax's phage display patents known as the Ladner patents.
The agreement also provides for a release of Dyax and its collaborators from claims under the XOMA patents arising from any past activities using Dyax technology to the extent they also used XOMA's antibody expression technology and allows Dyax to use the XOMA technology in combination with its own technology in any future collaborations.
"We are very pleased to enter into this antibody related licensing arrangement with Dyax, a company with excellent capabilities in the important field of antibody discovery and selection," said Jack Castello, Chairman, President and Chief Executive Officer, XOMA Ltd.
"Our license to Dyax, being the third such license this year with a significant antibody library company, further validates the fundamental position our antibody expression technology holds in the phage display arena. We are also pleased to expand our target discovery and therapeutic antibody development capabilities with the Dyax antibody library and a license to the Ladner patents, which are fundamental to the practice of antibody phage display."
"Through this agreement, Dyax is pleased to add XOMA's bacterial antibody expression technology to the package of technology and services we are able to provide to our current and future antibody technology customers," said Henry E. Blair, Chairman and CEO of Dyax Corp. "We are especially pleased to gain access to this key technology for Dyax's internal therapeutic product development and manufacturing programs." |
